论文部分内容阅读
目的研究ELAC2在体内外对前列腺癌生长的影响。方法利用脂质体转染法将ELAC2基因转入Du-145细胞,建立稳定表达ELAC2的细胞株,同时设立未转染Du-145和转染空载体的Du-145/pcDNA3作为对照。采用RT-PCR和Western blot法检测转染前后ELAC2的mRNA和蛋白表达水平;MTT法检测细胞生长和增殖情况。采用BALB/c裸鼠建立Du-145前列腺癌移植瘤动物模型,检测在体内ELAC2对前列腺癌生长的影响。结果 RT-PCR检测结果显示,ELAC2在Du-145/ELAC2细胞中mRNA表达明显增加,Western blot法检测同样发现ELAC2蛋白表达水平显著升高。MTT检测结果表明,Du-145/ELAC2细胞增殖较对照组细胞明显减缓(P<0.05)。在体内,Du-145/ELAC2组平均瘤质量和瘤体积均较对照组明显降低(P<0.05)。结论提高ELAC2基因表达水平能明显抑制体内外前列腺癌细胞Du-145的生长,提示ELAC2可作为前列腺癌治疗的一个新基因。
Objective To study the effect of ELAC2 on the growth of prostate cancer in vitro and in vivo. Methods ELAC2 gene was transfected into Du-145 cells by lipofection method. The cell line stably expressing ELAC2 was established. At the same time, Du-145 / pcDNA3 transfected with Du-145 and empty vector were used as controls. The mRNA and protein expression of ELAC2 before and after transfection were detected by RT-PCR and Western blot. The cell growth and proliferation were detected by MTT assay. Du-145 prostate cancer xenograft model was established by BALB / c nude mice and the effect of ELAC2 on the growth of prostate cancer in vivo was examined. Results The results of RT-PCR showed that ELAC2 mRNA expression was significantly increased in Du-145 / ELAC2 cells. Western blot also showed that ELAC2 protein expression was significantly increased. MTT assay showed that the proliferation of Du-145 / ELAC2 cells was significantly slower than that of the control group (P <0.05). In vivo, the average tumor mass and tumor volume in Du-145 / ELAC2 group were significantly lower than those in control group (P <0.05). Conclusion Increasing ELAC2 gene expression can significantly inhibit the growth of Du-145 prostate cancer cells in vitro and in vivo, suggesting that ELAC2 may serve as a new gene for the treatment of prostate cancer.